Status:
UNKNOWN
A Registry Study on Biomarkers of Pulmonary Embolism
Lead Sponsor:
Beijing Institute of Heart, Lung and Blood Vessel Diseases
Conditions:
Pulmonary Embolism
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to evaluate the value of biomarkers in the diagnosis and risk stratification of patients with suspected pulmonary embolism.
Detailed Description
Management of patients with acute pulmonary embolism is a serious problem. The rapid and accurate diagnosis and risk stratification of these patients is an important unmet clinical need. The aim of th...
Eligibility Criteria
Inclusion
- Patient aged ≥ 18 years that presents to an emergency department
- With suspected PE defined as new onset of or worsening of shortness of breath or chest pain
Exclusion
- Hemodynamic instability
- Life expectancy less than 3 months
- First symptoms 15 day or more before inclusion
- Inability to the follow-up visits
- Therapeutic anticoagulation for any indication
Key Trial Info
Start Date :
April 18 2015
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2021
Estimated Enrollment :
480 Patients enrolled
Trial Details
Trial ID
NCT04118634
Start Date
April 18 2015
End Date
August 1 2021
Last Update
December 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China, 100029